On September 1, 2020 Carlyle Group, a US private equity firm, reported that invested $260 million in Shenzhen Salubris Pharma to buy a 5% stake. Salubris makes finished drugs and medical devices for cardiovascular, oncology and anti-infective needs (Press release, Salubris Pharmaceuticals, SEP 1, 2020, View Source [SID1234564462]). In a statement, Carlyle said China’s new methods of reimbursement will cause consolidation among domestic generic drug companies, giving the surviving companies greater market share. With Carlyle’s help, Salubris will expand into the US, possibly through M&A.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!